返回
Clarity Pharmaceuticals Ltd（CLRPF）價格
CLRPF 股價走勢圖
CLRPF 收益
Clarity Pharmaceuticals Ltd
$2.3
2.22%
$0.04
收盤價：Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
盤後：Jan 16, 20:00:00 GMT-5
關鍵數據
前收市價
$2.25
開盤價
$2.3
當日範圍
$2.3 - $2.3
52週區間
$0.842 - $3.6
交易量
--
平均成交量
3.1K
每股盈餘 (TTM)
-0.13
股息收益率
--
市值
$855.6M
什麼是 CLRPF？
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing targeted copper theranostics based on its SAR Technology Platform. The company is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.